| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/0166-3542(90)90001-N |
| P698 | PubMed publication ID | 2088205 |
| P2093 | author name string | Shipman C Jr | |
| Prichard MN | |||
| P433 | issue | 4-5 | |
| P921 | main subject | drug interaction | Q718753 |
| P304 | page(s) | 181-205 | |
| P577 | publication date | 1990-10-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | A three-dimensional model to analyze drug-drug interactions | |
| P478 | volume | 14 |
| Q28378894 | 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity |
| Q41996877 | A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease |
| Q26700115 | A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus |
| Q41745036 | A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling |
| Q35627868 | A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments |
| Q44284081 | A checkerboard method to evaluate interactions between drugs |
| Q37801589 | A few specialized issues that should be focused on anti-HIV drug evaluation in vitro |
| Q52372013 | A general formulation of the concept of independent action for the combined effects of agents. |
| Q92608671 | A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo |
| Q40125731 | A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus |
| Q37394783 | A semiparametric response surface model for assessing drug interaction |
| Q33620098 | A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. |
| Q35641039 | AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets |
| Q47643551 | ATR Is a Therapeutic Target in Synovial Sarcoma. |
| Q36413964 | AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair |
| Q27315948 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer |
| Q37734561 | Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections |
| Q37072113 | Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections |
| Q28379173 | Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro |
| Q34510424 | Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections |
| Q42290805 | Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition |
| Q39191241 | Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model |
| Q34416737 | Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I |
| Q36770118 | An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission |
| Q33580906 | An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines |
| Q97884923 | An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis |
| Q37091715 | Analyses of the combination of 6-MP and dasatinib in cell culture |
| Q38546567 | Analysis of drug combinations: current methodological landscape |
| Q42989230 | Analysis of the combined effect of two linear inhibitors on a single enzyme |
| Q36924097 | Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells |
| Q42545418 | Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses |
| Q40834269 | Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication |
| Q42400705 | Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine |
| Q28369925 | Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication |
| Q91823296 | Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle |
| Q35126768 | Antimicrobial activity of human pancreatic juice and its interaction with antibiotics |
| Q34540677 | Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile |
| Q38904239 | Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections. |
| Q89864933 | Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 |
| Q39872168 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor |
| Q73194024 | Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT |
| Q59356117 | Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus |
| Q45393862 | Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of Herpes simplex virus type 1 alone and in combination with acyclovir |
| Q38943015 | Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection |
| Q30968332 | Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. |
| Q35751916 | Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents |
| Q41560215 | Antiviral phospholipids. Anti-HIV drugs conjugated to the glycerobackbone of phospholipids |
| Q28344048 | Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus |
| Q37718693 | Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. |
| Q54943391 | Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis. |
| Q28551925 | Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase |
| Q28367552 | Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro |
| Q47115739 | Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism |
| Q28344042 | Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon |
| Q35956560 | CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant |
| Q41466400 | CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. |
| Q35270714 | CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections |
| Q59332975 | COMBImage: a modular parallel processing framework for pairwise drug combination analysis that quantifies temporal changes in label-free video microscopy movies |
| Q28551538 | Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 |
| Q42550839 | Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. |
| Q92861777 | Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat Escherichia coli Harboring bla NDM- 5 and mcr-1 |
| Q39788218 | Combenefit: an interactive platform for the analysis and visualization of drug combinations. |
| Q30408112 | Combination chemotherapy for influenza |
| Q30364319 | Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. |
| Q40425026 | Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells |
| Q71860904 | Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections |
| Q36058012 | Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer |
| Q28076891 | Combination therapeutics in complex diseases |
| Q39102455 | Combinations of 1,8-cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice |
| Q27486821 | Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance |
| Q30401138 | Combinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice |
| Q30414428 | Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice |
| Q34159076 | Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice |
| Q30400060 | Combinatorial approaches to the prevention and treatment of HIV-1 infection |
| Q33935329 | Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro |
| Q38737793 | Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism |
| Q28343171 | Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir |
| Q35123092 | Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa |
| Q38694084 | Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies |
| Q44036336 | Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida. Impact on the development of buccal preparations of lactoferrin |
| Q40639328 | Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication |
| Q89642153 | Current Methods for Quantifying Drug Synergism |
| Q35270303 | Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. |
| Q42824904 | Cytotoxic interactive effects of dentin bonding components on mouse fibroblasts |
| Q38774522 | Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. |
| Q24645702 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors |
| Q36425068 | Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. |
| Q40618085 | Design and synthesis of acyclic nucleoside analogs with chlorinated imidazo[1,2-a]pyridine bases. |
| Q28377197 | Design, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infections |
| Q40324890 | Design, synthesis, and antiviral evaluation of some polyhalogenated indole C-nucleosides. |
| Q36593791 | Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. |
| Q40151324 | Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. |
| Q33962846 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| Q35656614 | Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization. |
| Q91743379 | Drug Combinations: Mathematical Modeling and Networking Methods |
| Q31430709 | Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. |
| Q37190793 | Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice |
| Q33559151 | Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice |
| Q40600840 | Efficacy of methylenecyclopropane analogs of nucleosides against herpesvirus replication in vitro |
| Q37018003 | Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs |
| Q38307252 | Environmentally oriented models and methods for the evaluation of drug × drug interaction effects. |
| Q39177270 | Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha |
| Q37124096 | Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs |
| Q39871877 | Evaluation of antiviral drug synergy in an infectious HCV system |
| Q27457152 | Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever |
| Q28378655 | Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1 |
| Q38903149 | Experimental design and statistical analysis for three-drug combination studies |
| Q38894985 | Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study |
| Q39692280 | F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. |
| Q99637289 | Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion |
| Q47217844 | From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. |
| Q59358332 | GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo |
| Q38351481 | Helicase-primase as a target of new therapies for herpes simplex virus infections. |
| Q28368978 | Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 |
| Q28379523 | Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates |
| Q40271516 | Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape |
| Q34933094 | INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. |
| Q56355770 | Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures |
| Q36744202 | Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase |
| Q52654802 | Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy. |
| Q35865796 | Identification of small molecules acting against H1N1 influenza A virus |
| Q37203766 | In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71 |
| Q36075908 | In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. |
| Q42111140 | In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor |
| Q35103227 | In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses |
| Q37144780 | In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans |
| Q33857275 | In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication |
| Q24650264 | In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor |
| Q30356466 | In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. |
| Q37263490 | In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor |
| Q43509001 | In vitro and in vivo activity of eugenol on human herpesvirus. |
| Q37701604 | In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia |
| Q42181792 | In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. |
| Q41875646 | In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile |
| Q37643598 | In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor |
| Q40291210 | In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. |
| Q37544751 | In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. |
| Q35120219 | In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans |
| Q38898723 | In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. |
| Q39730865 | In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates |
| Q36425093 | In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods |
| Q40277481 | In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance |
| Q104135019 | In vitro synergy of isavuconazole in combination with colistin against Candida auris |
| Q40093537 | Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication |
| Q35738585 | Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone |
| Q39541397 | Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers |
| Q37450711 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides |
| Q39929713 | Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. |
| Q28368061 | Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system |
| Q37568962 | Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms |
| Q28367610 | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog |
| Q24656023 | Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent |
| Q40759962 | Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues |
| Q28379468 | Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins |
| Q92369681 | Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin |
| Q30353074 | Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828). |
| Q33798180 | Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses. |
| Q39152245 | Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines |
| Q28379301 | Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice |
| Q64244918 | Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers |
| Q35124345 | Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. |
| Q40701437 | Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus |
| Q39743397 | Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. |
| Q50238755 | Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting subunit Alpha 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses. |
| Q38709267 | Interferon-β and Interferon-γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays |
| Q24651415 | Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication |
| Q38848491 | Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination |
| Q89864916 | Lactoferrin is broadly active against yeasts and highly synergistic with amphotericin B |
| Q27663609 | Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 |
| Q36494323 | Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses |
| Q37618276 | M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures |
| Q34276394 | MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants |
| Q27490545 | MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease |
| Q34123595 | Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity |
| Q37164915 | Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma |
| Q53378831 | Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. |
| Q27477455 | NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon |
| Q24559989 | Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells |
| Q30355297 | New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion |
| Q28367654 | New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs |
| Q28484821 | Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects |
| Q42355202 | Nonlinear response surface in the study of interaction analysis of three combination drugs |
| Q28343467 | Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus |
| Q37624964 | Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase |
| Q44878466 | On testing for drug/chemical interactions: definitions and inference |
| Q37624896 | Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections |
| Q36949482 | Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice |
| Q28371767 | PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms |
| Q39265679 | Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells |
| Q35385360 | Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C |
| Q48786945 | Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution |
| Q40622883 | Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. |
| Q38850319 | Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action |
| Q34506788 | Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection |
| Q28320362 | Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event |
| Q36586345 | Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease |
| Q36703042 | Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs |
| Q37119654 | Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole |
| Q27487391 | Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) |
| Q40034799 | Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease |
| Q39658512 | Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease |
| Q27679235 | Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase |
| Q58100708 | Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator Against the Hepatitis B Virus |
| Q35076802 | Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit |
| Q36558549 | Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase |
| Q41907539 | Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A |
| Q37544769 | Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. |
| Q39902300 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase |
| Q51738220 | Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. |
| Q33797858 | Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor |
| Q34470890 | Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. |
| Q45973213 | Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. |
| Q27477522 | Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine |
| Q37544484 | Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon |
| Q37350856 | Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir |
| Q49496609 | Rifampicin-Manuka Honey Combinations Are Superior to Other Antibiotic-Manuka Honey Combinations in Eradicating Staphylococcus aureus Biofilms. |
| Q40193825 | Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice |
| Q28378823 | SC-52151, a novel inhibitor of the human immunodeficiency virus protease |
| Q27490844 | SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro |
| Q28346130 | SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 |
| Q35759004 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase |
| Q39206489 | Semisupervised Learning Based Disease-Symptom and Symptom-Therapeutic Substance Relation Extraction from Biomedical Literature. |
| Q26700073 | Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy |
| Q40263167 | Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. |
| Q40980835 | Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin |
| Q38971847 | Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity. |
| Q42168234 | Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development |
| Q35810447 | Strategic design and three-dimensional analysis of antiviral drug combinations |
| Q28378796 | Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide |
| Q36274964 | Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0. |
| Q39869987 | Substituted imidazopyridines as potent inhibitors of HCV replication |
| Q41440361 | Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides |
| Q38693891 | Synergistic Antiviral activity of Sofosbuvir and Type -I Interferons (α and β) against Zika virus |
| Q27477551 | Synergistic In Vitro Interactions between Alpha Interferon and Ribavirin against Bovine Viral Diarrhea Virus and Yellow Fever Virus as Surrogate Models of Hepatitis C Virus Replication |
| Q40220128 | Synergistic combination effect of cidofovir and idoxuridine on vaccinia virus replication |
| Q30359363 | Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. |
| Q41539985 | Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection |
| Q36295446 | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses |
| Q24550639 | Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates |
| Q40341465 | Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. |
| Q39161979 | Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention |
| Q44438126 | Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro |
| Q35135565 | Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. |
| Q40600824 | Synthesis and antiviral activity of 2-substituted analogs of triciribine |
| Q40969017 | Synthesis and antiviral activity of novel aza-acyclonucleosides. |
| Q40324876 | Synthesis and antiviral activity of some 2-substituted 3-formyl- and 3-cyano-5,6-dichloroindole nucleosides. |
| Q40530573 | Synthesis and antiviral evaluation of some novel tricyclic pyrazolo[3,4-b]indole nucleosides. |
| Q46912385 | Synthesis of 3-aminoimidazo[4,5-c]pyrazole nucleoside via the N-N bond formation strategy as a [5:5] fused analog of adenosine |
| Q51934858 | Systems biology and combination therapy in the quest for clinical efficacy. |
| Q39771532 | TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. |
| Q52692811 | Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. |
| Q40951880 | Testing drug additivity based on monotherapies |
| Q40773451 | The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. |
| Q57790436 | The NCI Transcriptional Pharmacodynamics Workbench: a tool to examine dynamic expression profiling of therapeutic response in the NCI-60 cell line panel |
| Q41194566 | The Synergistic Effect of Azoles and Fluoxetine against Resistant Candida albicans Strains Is Attributed to Attenuating Fungal Virulence |
| Q39205134 | The antimalarial ferroquine is an inhibitor of hepatitis C virus. |
| Q42539366 | The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture |
| Q33797891 | The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance |
| Q43039715 | The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy |
| Q38988957 | The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon |
| Q39865219 | The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions |
| Q39702043 | The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors |
| Q35867431 | The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli. |
| Q34504825 | The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro |
| Q35132378 | The population dynamics of antimicrobial chemotherapy. |
| Q39256583 | The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination |
| Q90106978 | The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma |
| Q33979237 | The triple combination indinavir-zidovudine-lamivudine is highly synergistic |
| Q39852169 | The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study |
| Q41226219 | Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures |
| Q38409231 | Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes |
| Q41546154 | Thiazolobenzimidazole: Biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor |
| Q40824788 | Thio Derivatives of 2(5H)-Furanone as Inhibitors against Bacillus subtilis Biofilms. |
| Q33743500 | Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine |
| Q21142648 | Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro |
| Q30379095 | Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. |
| Q73905120 | UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines |
| Q28343461 | Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide |
| Q30010631 | Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction |
| Q27473228 | VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells |
| Q91883970 | Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid |
| Q27489390 | Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus |
| Q36262458 | Withania somnifera Root Extract Enhances Chemotherapy through 'Priming'. |
| Q93240536 | uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions |
| Q35921211 | β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. |
| Q38972819 | β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism. |
Search more.